Home » Stocks » LJPC

La Jolla Pharmaceutical Company (LJPC)

Stock Price: $3.56 USD -0.29 (-7.53%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $3.60 +0.04 (1.12%) Oct 28, 7:53 PM

Stock Price Chart

Key Info

Market Cap 97.41M
Revenue (ttm) 26.35M
Net Income (ttm) -78.59M
Shares Out 27.36M
EPS (ttm) -2.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $3.56
Previous Close $3.85
Change ($) -0.29
Change (%) -7.53%
Day's Open 3.80
Day's Range 3.55 - 3.81
Day's Volume 387,285
52-Week Range 2.30 - 9.38

More Stats

Market Cap 97.41M
Enterprise Value 50.39M
Earnings Date (est) Mar 8, 2021
Ex-Dividend Date n/a
Shares Outstanding 27.36M
Float 26.96M
EPS (basic) -2.90
EPS (diluted) -2.89
FCF / Share -1.97
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.40M
Short Ratio 8.63
Short % of Float 12.61%
Beta 2.53
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.70
PB Ratio n/a
Revenue 26.35M
Operating Income -74.84M
Net Income -78.59M
Free Cash Flow -53.74M
Net Cash 47.02M
Net Cash / Share 1.72
Gross Margin 78.41%
Operating Margin -284.00%
Profit Margin -298.20%
FCF Margin -203.94%
ROA -32.56%
ROE -686.50%
ROIC -145.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.67*
(199.72% upside)
Low
4.00
Current: $3.56
High
20.00
Target: 10.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue23.0510.06-0.621.06-----
Revenue Growth129.26%---41.72%------
Gross Profit20.668.41-0.621.06-----
Operating Income-110-194-115-78.37-41.97-21.34-17.94-10.74-2.27-3.93
Net Income-117-199-115-78.19-41.91-21.31-17.94-7.74-11.55-3.76
Shares Outstanding27.1125.4221.2217.2315.6510.671.540.200.010.02
Earnings Per Share-4.30-7.85-5.41-4.54-2.68-2.00-12.16-41.77-1,579.50-250.00
Operating Cash Flow-84.95-152-85.08-58.71-25.18-12.88-4.73-2.14-1.83-3.39
Capital Expenditures-0.70-2.34-9.19-2.22-1.82-0.26-0.04---
Free Cash Flow-85.65-155-94.28-60.93-27.00-13.14-4.78-2.14-1.83-3.39
Cash & Equivalents88.7317491.8265.9312748.598.673.415.046.87
Total Debt26.48---------
Net Cash / Debt62.2517491.8265.9312748.598.673.415.046.87
Assets13220412070.8012950.548.753.435.106.93
Liabilities18816831.349.764.822.081.090.2220.666.45
Book Value-55.9935.9288.2061.0412548.467.653.21-15.560.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name La Jolla Pharmaceutical Company
Country United States
Employees 90
CEO Larry Edwards

Stock Information

Ticker Symbol LJPC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LJPC
IPO Date June 3, 1994

Description

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.